港股異動丨四環醫藥(0460.HK)高開近5% 附屬獲“國家隊”入股
格隆匯8月24日丨繼上週五大漲超17%後,四環醫藥(0460.HK)今日再度高開近5%,報1.08港元,本月累計漲幅超36%,股價創去年11月以來新高,總市值102億港元。四環醫藥公佈,於8月21日來自國家開發投資集團的該等投資者認購公司附屬軒竹(石家莊)合共18.6%的股權,總代價為8億元人民幣(相等於約8.97億港元)。該等投資者包括國家財政部、國投、招商局資本控股、北京首鋼基金及天津國資委等。認購事項的所得款項用於進一步開發集團的中後期臨牀產品管線及引進更多後期產品項目。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.